Your browser doesn't support javascript.
loading
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
Carey, Lisa A; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Diéras, Véronique; Dalenc, Florence; Diamond, Jennifer R; Fontaine, Christel; Wang, Grace; Rugo, Hope S; Hurvitz, Sara A; Kalinsky, Kevin; O'Shaughnessy, Joyce; Loibl, Sibylle; Gianni, Luca; Piccart, Martine; Zhu, Yanni; Delaney, Rosemary; Phan, See; Cortés, Javier.
Affiliation
  • Carey LA; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Lisa_Carey@med.unc.edu.
  • Loirat D; Medical Oncology Department and D3i, Institut Curie, Paris, France.
  • Punie K; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Bardia A; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Diéras V; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
  • Dalenc F; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
  • Diamond JR; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Fontaine C; Medical Oncology Department, Oncologisch Centrum, UZ Brussel, Brussels, Belgium.
  • Wang G; Miami Cancer Institute, Miami, FL, USA.
  • Rugo HS; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Hurvitz SA; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Kalinsky K; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
  • Loibl S; Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.
  • Gianni L; Medical Oncology, Gianni Bonadonna Foundation, Milan, Italy.
  • Piccart M; Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.
  • Zhu Y; Department of Biostatistics, Gilead Sciences, Inc, Foster City, CA, USA.
  • Delaney R; Department of Clinical Research, Gilead Sciences, Inc, Morris Plains, NJ, USA.
  • Phan S; Department of Clinical Development, Gilead Sciences Inc, Foster City, CA, USA.
  • Cortés J; International Breast Cancer Center, Quirón Group, Barcelona, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
NPJ Breast Cancer ; 8(1): 72, 2022 Jun 09.
Article in En | MEDLINE | ID: mdl-35680967
ABSTRACT
Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Breast Cancer Year: 2022 Document type: Article Affiliation country: United States